A placebo controlled trial of viloxazine with and without tranquillizers in depressive illness.
Two double-blind four-way crossover studies are reported, comparing the antidepressant effect of 14-day courses of: viloxazine, viloxazine with a tranquillizer either perphenazine or diazepam or tranquillizer alone, against a placebo. In one study the antidepressant effect of viloxazine at a dose of 150 mg daily was statistically greater than that of placebo, whilst in the second study viloxazine was statistically superior to diazepam (15 mg daily). In depressed patients with a clear anxiety component, viloxazine alone seemed preferable to a combination with a tranquillizer as such a combination did not produce an enhanced clinical effect and the incidence of side-effects was possibly increased. Viloxazine was generally well tolerated and side-effects, when they occurred, were generally a mild upper gastro-intestinal disturbance.
D003866:Depressive Disorder / Q000188:drug therapy*; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010546:Perphenazine / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D014745:Viloxazine / Q000009:adverse effects / Q000627:therapeutic use*
D010919:Placebos; D014745:Viloxazine; D010546:Perphenazine; D003975:Diazepam